June 18
1:00 pm - 2:00 pm EDT


New ASCO data: Early detection with WGS-based ctDNA tracking up to 1800 variants

NeXT Personal molecular residual disease (MRD) assay was featured in five presentations and posters at ASCO. Key highlights include:

  • Predicting relapse in patients with early stage breast cancer,
  • Immunotherapy treatment monitoring, pan-cancer with prognostic and predictive results,
  • Therapy monitoring in patients with gastrointestinal (GI) cancers.

Join this webinar to:

  • Ask questions about the NeXT Personal MRD ASCO data,
  • Discuss implications for clinical trial work,
  • Discover upcoming studies and publications.

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Christian Haudenschild

Christian Haudenschild

Senior Vice President, Genomic Laboratory Operations, Personalis

Dr. Haudenschild joined Personalis in 2012 to build the company's professional services department. Previously, he was an Associate Director at Illumina Inc., leading commercial sequencing. At Lynx Therapeutics and Solexa, he developed massively parallel protocols for studying small RNA and DNA. Dr. Haudenschild received his Ph.D. in Molecular and Cellular Enzymology from the University Louis Pasteur in 1995 and completed postdoctoral research at Washington State University and the University of California at Berkeley.

Richard Chen

Richard Chen

Executive Vice President, R&D, and Chief Medical Officer, Personalis

Dr. Chen joined Personalis in 2011 as Chief Scientific Officer and was promoted to Senior Vice President R&D and Chief Medical Officer in 2021. A physician scientist, Dr. Chen has extensive expertise in systems biology, translational genomics, knowledge engineering, and scientific product development. He co-founded and served on the board of several companies, including Ingenuity Systems. Dr. Chen has also served on the clinical faculty at Stanford University School of Medicine. He received a BS in Computer Science, an MD, and an MS in biomedical informatics from Stanford. He completed his Chief Residency and Dermatology Specialty Training at Stanford and is board certified.

Christelle Johnson

Christelle Johnson

Field Applications Scientist, Personalis

Christelle Johnson, PhD, is an Associate Director and Field Applications Scientist at Personalis, Inc., with over 9 years of experience in cancer genomics and immuno-oncology. She holds a PhD in Tumor Immunobiology from the University of Louisville School of Medicine and a Master's in Microbiology and Immunology from the American University of Beirut. Christelle has held postdoctoral research positions at Harvard Medical School and Cornell University. Her expertise spans research, clinical applications, and business, making her a well-rounded professional in the field of biomedical sciences.

Olga Alexeeva

Olga Alexeeva

Strategy Director, Personalis

Olga Alexeeva, a Stanford MBA graduate and former McKinsey consultant, has over 10 years of strategic leadership experience in biopharma and laboratory devices. As Director at Personalis, she organizes efforts for the company-wide product portfolio and is launching NeXT Personal molecular residual disease assay. At Natera, Olga drove the usage and expansion of Signatera MRD in genitourinary cancers by working with cross-functional teams on data generation, KOL relationships, sales training, and fueling pharma collaboration.